Literature DB >> 18060387

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Judith A Siuciak1, Sheryl A McCarthy, Douglas S Chapin, Ashley N Martin.   

Abstract

RATIONALE: Phosphodiesterases (PDEs) belonging to the PDE4 family control intracellular concentrations of cyclic adenosine monophosphate (cAMP) by catalyzing its hydrolysis. Four separate PDE4 genes (PDE4A, PDE4B, PDE4C, and PDE4D) have been identified. PDE4 has been reported to be involved in various central nervous system (CNS) functions including depression, memory, and schizophrenia, although the specific subtype mediating these effects remains unclear.
OBJECTIVE: To investigate the role of PDE4B in the CNS, PDE4B wild-type and knockout mice (C57BL/6N background) were assessed in a variety of well-characterized behavioral tasks, and their brains were assayed for monoamine content.
RESULTS: Knockout mice showed a significant reduction in prepulse inhibition. Spontaneous locomotor activity was decreased (16%) in knockout mice. Furthermore, when challenged with amphetamine, both groups of mice responded similarly to a low dose of d-amphetamine (1.0 mg/kg), but knockout mice showed an enhanced response to a higher dose (1.78 mg/kg). Decreases in baseline levels of monoamines and their metabolites within the striatum of knockout mice were also observed. PDE4B knockout mice showed a modest decrease in immobility time in the forced swim test that approached significance. In several other tests, including the elevated plus maze, hot plate, passive avoidance, and Morris water maze, wild-type and knockout mice performed similarly.
CONCLUSION: The present studies demonstrate decreased striatal DA and 5-HT activity in the PDE4B knockout mice associated with decreased prepulse inhibition, decreased baseline motor activity, and an exaggerated locomotor response to amphetamine. These data further support a role for PDE4B in psychiatric diseases and striatal function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18060387     DOI: 10.1007/s00213-007-1014-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  75 in total

1.  Forebrain D1 function and sensorimotor gating in rats: effects of D1 blockade, frontal lesions and dopamine denervation.

Authors:  Neal R Swerdlow; Jody M Shoemaker; Ronald Kuczenski; Michele J Bongiovanni; Alaina C Neary; Laura S Tochen; Richard L Saint Marie
Journal:  Neurosci Lett       Date:  2006-04-27       Impact factor: 3.046

2.  Functional dissociation between serotonergic pathways in dorsal and ventral hippocampus in psychotomimetic drug-induced locomotor hyperactivity and prepulse inhibition in rats.

Authors:  Snezana Kusljic; Maarten van den Buuse
Journal:  Eur J Neurosci       Date:  2004-12       Impact factor: 3.386

3.  Effect of Morris water maze diameter on visual-spatial learning in different mouse strains.

Authors:  Debby Van Dam; Guy Lenders; Peter Paul De Deyn
Journal:  Neurobiol Learn Mem       Date:  2005-11-14       Impact factor: 2.877

4.  Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.

Authors:  S J MacKenzie; M D Houslay
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

Review 5.  Phosphodiesterase inhibitors for cognitive enhancement.

Authors:  Gregory M Rose; Allen Hopper; Michael De Vivo; Ashok Tehim
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

6.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

Authors:  A Breier; T P Su; R Saunders; R E Carson; B S Kolachana; A de Bartolomeis; D R Weinberger; N Weisenfeld; A K Malhotra; W C Eckelman; D Pickar
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

7.  Localizing haloperidol effects on sensorimotor gating in a predictive model of antipsychotic potency.

Authors:  S Hart; M Zreik; R Carper; N R Swerdlow
Journal:  Pharmacol Biochem Behav       Date:  1998-09       Impact factor: 3.533

8.  Species differences in behavioural effects of rolipram and other adenosine cyclic 3H, 5H-monophosphate phosphodiesterase inhibitors.

Authors:  H Wachtel
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

9.  Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme.

Authors:  J A Siuciak; S A McCarthy; D S Chapin; T M Reed; C V Vorhees; D R Repaske
Journal:  Neuropharmacology       Date:  2007-04-29       Impact factor: 5.250

10.  Antinociceptive effect of brain-derived neurotrophic factor and neurotrophin-3.

Authors:  J A Siuciak; C A Altar; S J Wiegand; R M Lindsay
Journal:  Brain Res       Date:  1994-01-07       Impact factor: 3.252

View more
  45 in total

Review 1.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

2.  Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.

Authors:  Mahomi Kuroiwa; Gretchen L Snyder; Takahide Shuto; Atsuo Fukuda; Yuchio Yanagawa; David R Benavides; Angus C Nairn; James A Bibb; Paul Greengard; Akinori Nishi
Journal:  Psychopharmacology (Berl)       Date:  2011-08-11       Impact factor: 4.530

Review 3.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

Review 4.  PDE4 as a target for cognition enhancement.

Authors:  Wito Richter; Frank S Menniti; Han-Ting Zhang; Marco Conti
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

5.  Effects of repeated treatment with phosphodiesterase-4 inhibitors on cAMP signaling, hippocampal cell proliferation, and behavior in the forced-swim test.

Authors:  Lan Xiao; James P O'Callaghan; James M O'Donnell
Journal:  J Pharmacol Exp Ther       Date:  2011-05-12       Impact factor: 4.030

Review 6.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 7.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

8.  Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.

Authors:  Shaunna L Clark; Renan P Souza; Daniel E Adkins; Karolina Aberg; József Bukszár; Joseph L McClay; Patrick F Sullivan; Edwin J C G van den Oord
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

9.  Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B.

Authors:  Ren Zhang; Eleftheria Maratos-Flier; Jeffrey S Flier
Journal:  Endocrinology       Date:  2009-04-09       Impact factor: 4.736

Review 10.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.